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Abstract
Aims/hypothesis Maggots of the blowfly Lucilia sericata are
used for the treatment of chronic wounds. As monocytes
may contribute to the excessive inflammatory responses in
such wounds, this study focussed on the effects of maggot
secretions on the pro-inflammatory activities of these cells.
Methods Freshly isolated monocytes were incubated
with a range of secretions for 1 h and then stimulated with
lipopolysaccharides (range 0–100 ng/ml) or lipoteichoic acid
(range 0–5µg/ml) for 18 h. The expression of cell surface
molecules, cytokine and chemokine levels in culture super-
natants, cell viability, chemotaxis, and phagocytosis and
killing of Staphylococcus aureus were measured.
Results Maggot secretions dose-dependently inhibited pro-
duction of the pro-inflammatory cytokines TNF-α, IL-
12p40 and macrophage migration inhibitory factor by
lipopolysaccharides- and lipoteichoic acid-stimulated
monocytes, while enhancing production of the anti-
inflammatory cytokine IL-10. Expression of cell surface
receptors involved in pathogen recognition remained unaf-
fected by secretions. In addition, maggot secretions altered the
chemokine profile of monocytes by downregulating macro-
phage inflammatory protein-1β and upregulating monocyte
chemoattractant protein-1 and IL-8. Nevertheless, chemotac-
tic responses of monocytes were inhibited by secretions.
Furthermore, maggot secretions did not affect phagocytosis
and intracellular killing of S. aureus by human monocytes.
Finally, secretions induced a transient rise in the intracellular
cyclic AMP concentration in monocytes and Rp-cyclic
AMPS inhibited the effects of secretions.
Conclusions/interpretation Maggot secretions inhibit the
pro-inflammatory responses of human monocytes through
a cyclic AMP-dependent mechanism. Regulation of the
inflammatory processes by maggots contributes to their
beneficial effects on chronic wounds.
Keywords Chemokines . Chemotaxis . Chronic wounds .
Cyclic AMP. Cytokines . Inflammation . Phagocytosis .
Signal transduction
Abbreviations
cAMP Cyclic AMP
fMLP Formyl-Met-Leu-Phe
HBSS Hanks' buffered salt solution
MCP Monocyte chemoattractant protein
MIF Macrophage migration inhibitory factor
MIP Macrophage inflammatory protein
RANTES Regulated on activation, normal T cell
expressed and secreted
TLR Toll-like receptor
Introduction
Chronic wounds are common in patients with vascular
insufficiencies and underlying chronic conditions such as
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diabetes mellitus, as well as patients suffering from acute,
extended trauma [1]. Up to 15% of the more than 200
million diabetes patients worldwide develop a foot ulcer at
some stage, leading to over one million amputations every
year [2]. The importance of chronic wounds in the pathway
to lower limb amputation is paramount, as 84% of
amputations are preceded by a diabetic foot ulcer [3].
Chronic wounds and amputations in persons with diabetes
often result in decreased physical, emotional and social
function of patients, a reduced quality of life and major
economic costs for both the patients, their families and
society [4, 5].
Sterile larvae (maggots) of the blowfly Lucilia sericata
are used for the treatment of different types of wounds
including diabetic foot ulcers [6–9]. The success rate of this
therapy is around 68% for wounds unresponsive to
conventional therapies, although some characteristics
(chronic limb ischaemia, wound depth and age) may
negatively influence the outcome [8]. Besides the removal
of necrotised tissue and infectious microorganisms, mag-
gots may promote fibroblast migration and tissue remodel-
ling [10]. Moreover, maggot secretions potently inhibit the
pro-inflammatory responses of human neutrophils without
affecting their antimicrobial activities [11]. Another prom-
inent type of phagocyte in wounds is the monocyte. In
response to chemotactic substances these cells migrate from
the blood into the infected tissue to combat invading
microorganisms. In addition, monocytes regulate the in-
flammatory process by secreting cytokines and growth
factors, thereby recruiting more inflammatory cells as well
as by antigen processing/presentation and lymphocyte
activation.
In contrast to acute wound healing, chronic wounds
are marked by a prolonged and dysregulated inflamma-
tory phase. Inflammatory cells like neutrophils, mono-
cytes and macrophages are not only present in excess
numbers [12–14], they also have enhanced production and
release of pro-inflammatory cytokines, proteases and
reactive oxygen species, leading to growth factor inacti-
vation and tissue destruction [15]. Therefore, inhibition of
the pro-inflammatory responses of these cells could
restrict their deleterious effects and thus contribute to
healing processes. To obtain more insight into the
mechanisms underlying the beneficial effects of medicinal
maggots, this study focussed on the effects of maggot
excretions and/or secretions on the pro-inflammatory
activities of human monocytes.
Methods
Maggots and their excretions/secretions Sterile second- and
third-instar larvae of L. sericata were a kind gift from
BioMonde (Barsbüttel, Germany). Maggot excretions/
secretions were collected as previously described [11].
Next, maggots were incubated for 1 h in H2O to remove
their excretions, washed and then their secretions were
collected as described for excretions/secretions. In the
assays excretions/secretions and secretions alone were
tested simultaneously.
Isolation of human monocytes Peripheral blood mononu-
clear cells from healthy donors were isolated from buffy
coats by Ficoll amidotrizoate (ρ=1.077 g/ml) density
centrifugation at 700×g for 20 min. Cells from the
interphase were washed three times and monocytes were
purified using anti-CD14-coated Microbeads (Miltenyi
Biotec, Bergisch Gladbach, Germany). When testing
antimicrobial activities, cells in the interphase were used
to avoid possible functional impairment of the monocytes
by the interaction of CD14 with anti-CD14 coated microbe-
ads. For the chemotaxis assay lymphocytes were removed
from the interphase using anti-CD3 microbeads (Miltenyi)
to avoid obstruction of the filters by large numbers of these
cells.
Stimulation of monocytes Approximately 1×106 mono-
cytes/ml of RPMI-1640 supplemented with 2 mmol/
l glutamax-I/glutamine, 2 mmol/l penicillin/streptomycin
and 10% (vol./vol.) inactivated fetal calf serum (standard
medium) were transferred to wells of a 24-well plate and
incubated with excretions/secretions and secretions alone
or, as a control, H2O for 1 h followed by stimulation with
lipopolysaccharides (Sigma Chemical Co., St Louis, MO,
USA), lipoteichoic acid (Invivogen, Toulouse, France) or
no stimulus. After 18 to 22 h of incubation at 37°C and
5% CO2, supernatant fractions were collected and stored
at −70°C.
Measurement of cytokine and chemokine levels The cyto-
kine and chemokine levels in the supernatant fractions of
cell cultures were assessed using kits (BioSource CytoSet;
Biosource Europe, Nivelles, Belgium; and Bio-Plex; BIO-
RAD, Hercules, CA, USA).
Chemotaxis Migration of monocytes was measured as
previously described [11] with the following modifications.
The lower compartments contained a mixture (vol./vol.) of
25% HEPES buffer and 75% supernatants from monocyte
cultures stimulated as described above. To test direct effects
of excretions/secretions and secretions alone on monocyte
migration, 10 nmol/l formyl-Met-Leu-Phe (fMLP) (Sigma)
was added as well. In the upper compartment, 50µl of 2×
106 monocytes/ml of RPMI-1640 were placed. Results are
expressed as the number of cells counted in 2μm2 areas in
11 subsequent levels within each filter.
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Phagocytosis assay Staphylococcus aureus Strain 42D of
S. aureus were grown overnight in tryptone soya broth
at 37°C while shaking, then washed and resuspended (1×
107/ml) in Hanks' buffered salt solution (HBSS) 0.1%
(vol./wt) gelatine. Equal volumes of this suspension and a
monocyte suspension (1×107/ml of HBSS–0.1% gelatine)
that had been freshly isolated or incubated for 18 h in
excretions/secretions or secretions alone were mixed and
10% (vol./vol.) AB-serum was added. Subsequently,
100μl of this mixture were transferred to hydron-coated
surface plates (Nunclon; Nalge Nunc International,
Rochester, NY, USA) containing excretions/secretions,
secretions alone or H2O. At various intervals after
incubation at 37°C while shaking, cells and bacteria were
collected in cold HBSS and centrifuged at 140×g for
6 min. Next, the number of non-cell-associated bacteria
was determined microbiologically using serial dilutions
plated on to agar plates. Phagocytosis is expressed as the
percentage decrease of non-cell-associated S. aureus.
Intracellular killing assay Opsonisation and intracellular
killing of S. aureus were done as previously described [16]
using hydron-coated plates (Nalge Nunc). Disruption of
monocytes was performed by collecting these cells in H2O
supplemented with 0.01% (vol./wt) BSA and then vortex-
ing these suspensions for 60 s. Killing is expressed as the
percentage decrease in the number of viable bacteria
determined as described above.
Flow cytometry Cells were incubated with FITC- or
phycoerythrin-conjugated monoclonal antibodies directed
against CD11b, CD14, CD32, CD35, CD54 and CD64
(BD Pharmingen; BD BioSciences, Erembodegem, Belgium),
and against CD16 (EuroBioSciences, Friesoythe, Germany),
CD282 (Toll-like receptor [TLR]-2) and CD284 (TLR-4;
Hycult Biotechnology, Uden, the Netherlands for both);
incubation was in PBS containing 0.5% (wt/vol.) BSA for
30 min on ice. Analyses were performed on FACSCalibur
(Becton Dickinson, La Jolla, CA, USA) in combination with
CellQuest Pro 4.0.2 software.
Cell viability Monocytes were stimulated and incubated as
described above and then incubated with fluorescence-
labelled Annexin V (2.5μg/ml; Sigma) and propidium
iodide (1μg/ml; Sigma) in 10 mmol/l HEPES (pH7.4) as
previously described [17]. The mean fluorescence intensi-
ties of the cells were analysed by flow cytometry.
Measurement of intracellular cyclic AMP concentration -
Monocytes in RPMI were incubated with a range of
excretions/secretions, secretions alone or no stimulus for
various intervals up to 2 min. The reaction was stopped by
adding lysis buffer. Next, the cyclic AMP (cAMP) content
of these samples was measured using an enzyme immuno-
assay system (cAMP Biotrak; Amersham Biosciences
Benelux, Roosendaal, the Netherlands). The cAMP con-
centrations were calculated from these values and the mean
cell volume of human monocytes [18].
Inhibition of cAMP-dependent protein kinase A Monocytes
were pre-incubated for 45 min with the protein kinase A
inhibitor adenosine-3′,5′-cyclic monophosphorothioate, tri-
ethyl ammonium salt (Rp-cAMPS; 1 mmol/l; BioLog Life
Science Institute, Bremen, Germany), followed by 1 h
Table 1 Effect of maggot secretions on lipopolysaccharide-induced production of various cytokines and chemokines by monocytes
Cytokine/chemokine Control cells Per cent induction by maggot secretions
Median (ng/ml) Range (ng/ml) 0.35µg/ml 3.5µg/ml 35µg/ml 70µg/ml
IL-1β 0.5 0.2–1.6 97±4 81±11 80±10 91±16
IL-6 25 13–40 89±7 95±4 92±11 116±15
IL-8 153 81–310 120±7* 121±9* 149±15* 268±63*
IL-10 0.4 0.05–2.1 108±8 142±11† 206±35† 209±35†
IL-12p40 0.3 0.1–5.4 98±6 82±6* 42±7† 39±10†
TNF-α 11 5–25 109±14 84±5* 29±5* 19±4*
MIF 0.08 0.04–0.2 85±21 41±14† 13±5† 5±3†
MCP-1 37 12–68 119±8 134±17 250±33† 367±66†
MIP-1β 20 1–155 107±11 104±20 23±9† 17±7*
RANTES 0.4 0.2–1.5 101±3 109±6 103±10 74±14
The results of the control cells, shown as median value and range, are set at 100%, with the effect of secretions expressed as a percentage of these
values
The results are means±SEM of six to ten experiments
*p<0.05, † p<0.005 for difference from control monocytes stimulated with lipopolysaccharides
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incubation with excretions/secretions,secretions alone or
H2O and stimulation for 18 to 22 h with 100 ng of
lipopolysaccharides/ml. Thereafter, cytokine production
was measured.
Statistical analysis Differences between the values for cells
incubated with excretions/secretions or secretions alone and
those for cells incubated with H2O were analysed with a
Wilcoxon test using Graphpad Prism version 4.02.
Results
Effect of secretions on monocyte cytokine and chemokine
production The results revealed that secretions decreased
lipopolysaccharides-induced production of the pro-
inflammatory cytokines TNF-α, IL-12p40 and macro-
phage migration inhibitory factor (MIF) by monocytes in
a dose-dependent manner without effecting IL-1β or IL-6
(Table 1). Production of the anti-inflammatory cytokine
IL-10 was increased by secretions. Secretions also
inhibited lipopolysaccharides-induced production of the
chemokine macrophage inflammatory protein (MIP)-1β
by monocytes and increased monocyte chemoattractant
protein (MCP)-1 and IL-8, but had no effect on RANTES
(regulated on activation, normal T cell expressed and
secreted). Secretions did not affect baseline levels of
IL-1β, IL-6, IL-10, IL-12p40, TNF-α, RANTES or MIP-
1β (data not shown). In contrast, 70µg of secretions/ml
increased production of MCP-1 by naive monocytes from
15 (range: 3–53) to 1,049 (range: 425–9,063)pg/ml and
that of IL-8 from 578 (range: 136–1,436) to 3,236 (range:
1,879–5,934)pg/ml, while decreasing production of MIF
from 72 (range: 19–318)pg/ml to below the detection limit
(10 pg/ml) when using 35 or 70µg of secretions/ml (n=6–8).
To determine whether the effective components are
secreted or excreted by maggots, we compared the effects
of secretions alone pools to excretions/secretions pools
from the same maggots on the cytokine and chemokine
profile of monocytes. The results showed that secretions
alone had better effects than excretions/secretions when
using equal protein concentrations (data not shown).
However, the protein concentration was 30±2% lower for
secretions alone than for excretions/secretions pools,
meaning that we used the products of more maggots when
testing secretions alone. Therefore, we tested the differ-
ences in effects when using the volume of the secretions
alone pools necessary to obtain 35µg for example, and used
the same volume for testing the excretions/secretions pools
(which was 50µg). The results showed that effects of
secretions alone and of excretions/secretions were equal,
indicating that the active component is secreted by
maggots. Therefore, we combined the results for secretions
alone and excretions/secretions and referred to them as
secretions.
Fig. 1 Effect of maggot secretions (35µg/ml) on the production of
TNF-α (a), IL-12p40 (b) and IL-10 (c) by monocytes challenged with
a range of lipopolysaccharide concentrations as indicated (log-scale).
The results are means and SEM of ten to 11 experiments. *p<0.05 and
†p<0.005 for difference from control-incubated monocytes stimulated
with lipopolysaccharides
Fig. 2 Effect of maggot secretions (35µg/ml) on the production of
TNF-α (a), IL-12p40 (b) and IL-10 (c) by monocytes challenged with
a range of lipoteichoic acid concentrations as indicated (log-scale).
The results are means and SEM of ten experiments. *p<0.05 and †p<
0.005 for difference from control-incubated monocytes stimulated
with lipoteichoic acid
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Effect of secretions on the sensitivity of monocytes to
lipopolysaccharides and lipoteichoic acid The results
revealed that the production of TNF-α by monocytes was
downregulated significantly by 35µg of secretions/ml for all
concentrations of lipopolysaccharides (Fig. 1a). Production of
IL-12p40 by monocytes was dose-dependently inhibited by
secretions (Fig. 1b), while production of IL-10 by monocytes
was enhanced (Fig. 1c). In addition, secretions (35µg/ml)
dose-dependently reduced the production of TNF-α (Fig. 2a)
and IL-12p40 (Fig. 2b) by monocytes in response to
lipoteichoic acid, while enhancing IL-10 (Fig. 2c).
Effect of culture supernatants of secretions-treated mono-
cytes on cell migration Since incubation of monocytes with
secretions altered production of several chemokines, we
investigated the effect of such monocyte culture super-
natants on migration of monocytes. The results revealed
that the chemotactic activity of monocytes towards culture
supernatants of lipopolysaccharides-stimulated monocytes
was abrogated when incubated in the presence of 35µg of
secretions/ml (Fig. 3a). Secretions did not induce migration
of naive monocytes. Interestingly, secretions blocked
migration of monocytes towards the chemotactic factor
fMLP (Fig. 3b). Furthermore, the chemotactic response of
monocytes towards combinations of monocyte culture
supernatants and fMLP was decreased in the presence of
secretions.
Effect of secretions on phagocytosis and intracellular
killing of S. aureus by monocytes The results showed that
secretions (3.5 and 35µg/ml) did not affect phagocytosis
and intracellular killing of S. aureus 42D by monocytes
(Table 2). The antibacterial functions of monocytes incu-
bated with secretions for 18 h were identical to those of
monocytes not incubated with secretions (data not shown).
Effect of secretions on cell surface receptors of monocytes The
results (Table 3) showed that secretions (35µg/ml) did not
affect expression of the pathogen-recognition receptors
CD282, CD284 and CD14 or that of the Fcγ receptors
CD16, CD32 and CD64, which are involved in the
phagocytosis of opsonised bacteria, except for a reduction
in lipopolysaccharides-induced expression of CD32
(FcRII). Additionally, expression of CD11b (together with
CD18 complement receptor 3), which is involved in
adhesion of monocytes to endothelial cells and phagocy-
tosis of bacteria, was enhanced by secretions, while
complement receptor 1 (CD35) expression was not
affected. CD54 expression was enhanced by secretions
on naive, but not on lipopolysaccharides-stimulated, cells.
Effect of secretions on the viability of monocytes The
results showed that secretions dose-dependently enhanced
the percentage of viable monocytes (Table 4). Moreover,
the lipopolysaccharides-induced increase in monocyte-
survival was further enhanced by secretions.
Effect of secretions on the intracellular cAMP concentra-
tion Analysis of the results revealed the peak cAMP
concentration to be reached 15 s after addition of secretions
(35µg/ml), returning gradually to basal values at 120 s
(data not shown). Based on these results, the 15 s interval
was chosen to determine the dose–effect relation for
secretions. The results revealed that 3.5µg of secretions/
Table 2 Effect of maggot secretions on phagocytosis and intracellular
killing of Staphylococcus aureus by monocytes
Secretions (µg/ml) Phagocytosis (%) at
indicated intervals
Intracellular killing (%)
at indicated intervals
30 min 60 min 30 min 60 min
0 12±3 39±4 38±11 61±7
3.5 21±4 35±4 44±8 55±10
35 19±2 34±3 38±12 57±10
Results are means±SEM of six experiments
Fig. 3 Effect of maggot secretions on the chemotactic activity of
monocytes. Migration of monocytes in response to chemokines in
cell-culture supernatants without or with 10 nmol/l fMLP as indicated
was monitored using a Boyden microchemotaxis chamber. Results are
means and SEM of six experiments. Each experiment was performed
in quadruplicate. *p<0.05 for difference from monocytes stimulated
without secretions. S, secretions
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ml significantly enhanced cAMP concentrations, with a
maximum increase of 1.9-fold over basal level after
exposure to 70µg of secretions/ml (Table 5). In agreement
with the above, the cAMP-dependent protein kinase
A-inhibitor Rp-cAMPS (1 mmol/l) significantly attenuated
the inhibitory effect of secretions (35µg/ml) on the
lipopolysaccharides-stimulated production of TNF-α (from
71±5 to 41±12%; n=9; p<0.005) and of IL-12p40 (from
71±6 to 32±14%; p<0.005), whereas it completely
blocked (p<0.05) the increase in IL-10 production by
lipopolysaccharides-stimulated monocytes.
Discussion
The main conclusion from the present study is that maggot
secretions suppress the pro-inflammatory responses of
monocytes without affecting their antimicrobial activities.
This conclusion is based on the following observations.
First, secretions reduced production of the pro-
inflammatory cytokines IL-12p40, TNF-α and MIF by
lipopolysaccharides-stimulated monocytes, whereas produc-
tion of anti-inflammatory cytokine IL-10 was enhanced.
Addition of secretions to monocytes that had already been
exposed to lipopolysaccharides resulted in similar effects on
the cytokine profile, indicating that secretions can interfere
with an ongoing inflammatory reaction (data not shown). The
anti-inflammatory actions of secretions are not limited to
modulation of the TLR-4 pathway, as secretions exerted
similar effects on cells stimulated with a TLR-2 ligand.
Furthermore, secretions inhibited the lipopolysaccharides-
induced production of TNF-α and IL-12p40 by cells in
whole blood (M. J. A. van der Plas and P. H. Nibbering,
personal communication). However, production of the anti-
inflammatory cytokine IL-10 by blood cells was not
affected by secretions, suggesting that the secretions-
induced increase in IL-10 production by purified monocytes
may be counteracted by cellular/molecular components of
whole blood. The suggestion that maggots produce IL-10
[19] can be ruled out as it was withdrawn by the authors
(K. Y. Mumcuoglu, Department of Parasitology, Hebrew
University-Hadassah Medical School, Jerusalem, Israel,
personal communication).
Second, secretions decreased the chemotactic response
of monocytes to fMLP as well as to the chemotactic factors
in supernatant fractions of (lipopolysaccharides-stimulated)
monocyte cultures. These results are in agreement with our
earlier finding that excretions/secretions reduced the migra-
tion of human neutrophils towards fMLP [11]. The
secretions-induced production of chemotactic factor MCP-
1 and decreased production of migration inhibitor MIF by
monocytes did not increase migration, indicating that
secretions inhibited migration independently of the levels
of these chemokines; participation of MIP-1β inhibition
cannot be ruled out. The effect of secretions-induced
Lipopolysaccharides (100 ng/ml) Secretions (µg/ml) Survival (%)
No 0 52±6
No 0.35 54±7
No 3.5 58±5*
No 35 74±4*
No 70 80±2*
Yes 0 69±4*,†
Yes 35 80±3*,†
Table 4 Effect of maggot secre-
tions on the viability ofmonocytes
The results, expressed as the
percentage of viable cells, are
means±SEM of six to ten
experiments
*p<0.05, † p<0.005 for differ-
ence from control-incubated
monocytes
Surface molecule No stimulus Lipopolysaccharides (100 ng/ml)
0 S (35μg/ml) 0 S (35μg/ml)
CD14 27±3 26±3 68±12 60±5
CD282 34±2 34±2 14±2 13±2
CD284 32±2 29±2 22±5 18±2
CD16 15±4 12±2 ND ND
CD32 74±12 78±18 273±27 214±19*
CD64 31±14 35±18 8±1 8±1
CD35 31±4 28±3 29±3 28±3
CD11b 243±24 399±52† 74±14 122±21†
CD54 386±35 517±54† 1,365±71 1,293±60
Table 3 Effect of maggot secre-
tions on expression of surface
molecules on monocytes
The results, expressed as the
mean fluorescence intensity, are
means±SEM of six to ten
experiments
*p<0.05, † p<0.005 for differ-
ence from control-incubated
monocytes
ND, not detectable; S, secretions
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increase of IL-8 and CD11b levels were not tested within
our experimental setup. The increased expression of CD54
and CD11b on naive monocytes is unlikely to influence
chemotaxis as monocytes are triggered when migrating into
a wound.
Third, secretions did not affect the phagocytosis and
intracellular killing of S. aureus by freshly isolated
monocytes and by monocytes cultured for 18 h. This is in
agreement with our earlier findings that excretions/secre-
tions had no effect on the phagocytosis and intracellular
killing of Candida albicans by neutrophils [11]. Addition-
ally, maggots aid in the removal of bacteria from wounds
by ingesting bacteria together with liquefied necrotic tissue
and subsequently killing them in their digestive tract [20,
21]. An important implication of the above observations
that secretions interfered in a similar fashion with activation
of TLR-2 and TLR-4 pathways is that the reported
differences in effects of maggots on survival of gram-
positive and gram-negative bacteria [22] are likely to be the
result of antibacterial activity [1] and not of differential
modulation of immune cell responses.
Another major conclusion pertains to the mechanisms by
which secretions exert their effects on monocytes. Our
results showed that the effects of secretions on the cytokine/
chemokine profiles of lipopolysaccharides- and lipoteichoic
acid-stimulated monocytes were not caused by an altered
sensitivity to these stimuli. In agreement with this,
secretions also had no effect on expression of surface
molecules involved in the recognition of bacterial products
by (lipopolysaccharides-stimulated) monocytes, suggesting
that secretions exert their effects either downstream of these
receptors or on other, as yet unidentified (intracellular)
binding partners and targets. Based on our earlier finding
that excretions/secretions increased intracellular cAMP
levels in neutrophils [11], we assumed a similar mechanism
by monocytes and, indeed, found that cAMP concentrations
were dose- and time-dependently enhanced by secretions.
Pre-treating monocytes with Rp-cAMPS, an inhibitor of
cAMP-dependent protein kinase A-activation, attenuated
the effects of secretions on lipopolysaccharides-stimulated
cytokine production, indicating that maggots exert their
effects on monocytes through a cAMP-dependent mecha-
nism. Consistent with this, others have reported that
activation of cAMP pathways is associated with reduced
production of pro-inflammatory cytokines, including TNF-
α, IL-12 and MIP-1β, without affecting IL-1β production
and while enhancing production of IL-10 [23, 24].
Furthermore, cAMP-elevation is connected to decreased
migration [25, 26], whereas phagocytosis by freshly
isolated monocytes remains unaffected [27]. However,
elevation of cAMP was also associated with a moderate
reduction in phagocytosis by incubated/stimulated mono-
cytes and macrophages [27, 28], a finding that seems to be
in contrast with our data. This discrepancy can be explained
by our observation that secretions enhanced the viability of
monocytes, such that although the total phagocytosis of
bacteria remained the same, the amount of phagocytosis per
viable monocyte decreased. As secretions did not decrease
expression of FcR, CR1 or CD11b (part of CR3), the
reduction in phagocytosis per cell may be explained by
interference of signalling pathways downstream of receptor
activation [28]. Interestingly, cAMP is known to inhibit
apoptosis in several cell types [29–31].
What could be the clinical relevance of the present
findings? Although pro-inflammatory responses are essen-
tial for healing of acute wounds, they can be detrimental in
chronic wounds where inflammation persists. Some histo-
logical data suggest that parts of chronic wounds seem to be
stuck in different phases of healing with loss of the
synchronicity that leads to rapid healing [13]. Thus some
part ready for epidermal resurfacing and fibroblast prolif-
eration could be damaged by another part that is still in the
inflammatory phase [32]. Chronic leg ulcers are associated
with elevated levels of pro-inflammatory cytokines, like
TNF-α and MIF, compared with acute wounds [33–35].
These cytokines enhance the production and release of a
large variety of other pro-inflammatory cytokines [36, 37]
as well as the synthesis of several matrix metalloproteinases
and serine proteases [15, 37, 38]. When produced in excess
these pro-inflammatory responses may cause deleterious
extracellular matrix destruction [39–41], as well as growth
factor and protease inhibitor inactivation [38, 42–44], and
are responsible for the failure of wound healing. In
addition, TNF-α activates phagocytes to produce reactive
oxygen intermediates [45, 46], which can be toxic to cells
like endothelial cells, fibroblasts and leucocytes, and may
further promote tissue proteolysis by potentiating the
effects of several proteinases, while inactivating proteinase
inhibitors [47, 48]. Together, pro-inflammatory responses
may be responsible for maintaining the chronic status of
chronic wounds. Furthermore, TNF-α is also related to the
formation of ulcers through its enhancement of plasmino-
gen activator inhibitor-1 production [49, 50], which can
Table 5 Effect of maggot secretions on the cAMP concentration in
monocytes
Secretions (µg/ml) cAMP (µmol/l)
0 0.91±0.07
0.35 0.97±0.08
3.5 1.09±0.10*
35 1.33±0.13*
70 1.70±0.17*
Results are means±SEM of ten experiments
*p<0.05 for difference from control-incubated monocytes
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lead to impaired lysis of pericapillary fibrin cuffs [51].
Importantly, although the mechanisms underlying the im-
munomodulatory effects of maggot secretions on monocytes
are not fully elucidated, the findings from the present in vitro
study show that maggot secretions potently inhibit the pro-
inflammatory activities of monocytes. Secretions decrease
migration of cells to the wound and reduce the amount of
pro-inflammatory cytokines of the cells located in the wound,
while their overall antibacterial activities are unaltered.
Consequently, the release of other pro-inflammatory cyto-
kines, reactive oxygen intermediates and proteases will
diminish, bringing tissue destruction to a halt and possibly
resulting in an environment beneficial for healing.
The exciting beneficial effect of maggots in treatment of
diabetic foot ulcers and other chronic wounds, as found in
clinical studies [6–9], could be explained by the phenomena
described in this study. Apart from the direct antibacterial
features of maggots observed in other studies [20, 21] and
our earlier observations that excretions/secretions can
inhibit the formation and breakdown of bacterial biofilms
[1], we found that maggots seem to preserve the important
antibacterial function of human phagocytes, while protect-
ing the fragile regenerating wound-bed against inflamma-
tion and tissue destruction by the same inflammatory cells.
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